OPKO Health Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

OPKO Health wird ein Gewinn- und Umsatzwachstum von 43.3% bzw. 6.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 41.7% pro Jahr wachsen soll.

Wichtige Informationen

43.3%

Wachstumsrate der Gewinne

41.7%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	20.9%
Wachstumsrate der Einnahmen	6.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	13 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 09

Recent updates

OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 09

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:OPK - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	734	-70	12	N/A	3
12/31/2025	685	-218	-17	N/A	6
12/31/2024	685	-159	-183	N/A	6
9/30/2024	711	-134	-200	-177	N/A
6/30/2024	716	-243	-86	-67	N/A
3/31/2024	800	-252	-59	-41	N/A
12/31/2023	863	-189	-44	-28	N/A
9/30/2023	867	-208	-41	-22	N/A
6/30/2023	868	-209	-110	-87	N/A
3/31/2023	913	-291	-120	-98	N/A
12/31/2022	1,004	-328	-120	-95	N/A
9/30/2022	1,220	-317	-94	-69	N/A
6/30/2022	1,426	-202	-28	-4	N/A
3/31/2022	1,559	-117	-36	-8	N/A
12/31/2021	1,775	-30	6	38	N/A
9/30/2021	1,868	76	46	78	N/A
6/30/2021	1,910	71	73	108	N/A
3/31/2021	1,769	121	72	109	N/A
12/31/2020	1,435	31	6	39	N/A
9/30/2020	1,165	-114	-72	-41	N/A
6/30/2020	966	-200	-151	-128	N/A
3/31/2020	891	-293	-182	-167	N/A
12/31/2019	902	-315	-185	-173	N/A
9/30/2019	899	-279	-173	-161	N/A
6/30/2019	920	-244	-181	-159	N/A
3/31/2019	958	-191	-147	-123	N/A
12/31/2018	990	-153	-137	-109	N/A
9/30/2018	929	-295	-112	-72	N/A
6/30/2018	926	-303	N/A	-88	N/A
3/31/2018	955	-314	N/A	-94	N/A
12/31/2017	966	-305	N/A	-92	N/A
9/30/2017	1,081	-101	N/A	-64	N/A
6/30/2017	1,133	-80	N/A	-58	N/A
3/31/2017	1,197	-48	N/A	7	N/A
12/31/2016	1,117	-48	N/A	32	N/A
9/30/2016	1,222	-10	N/A	-8	N/A
6/30/2016	1,067	133	N/A	-7	N/A
3/31/2016	753	75	N/A	-84	N/A
12/31/2015	492	-30	N/A	164	N/A
9/30/2015	241	-85	N/A	149	N/A
6/30/2015	118	-262	N/A	159	N/A
3/31/2015	99	-244	N/A	171	N/A
12/31/2014	91	-172	N/A	-90	N/A
9/30/2014	86	-135	N/A	-92	N/A
6/30/2014	87	-147	N/A	-82	N/A
3/31/2014	87	-125	N/A	-64	N/A
12/31/2013	97	-115	N/A	-56	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: OPK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: OPK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: OPK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: OPKDie Einnahmen des Unternehmens (6.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: OPKDie Einnahmen des Unternehmens (6.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von OPK in 3 Jahren voraussichtlich hoch sein wird

OPKO Health Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to US$0.24 loss, revenue downgraded

OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

OPKO Health, Inc. Provides Financial Guidance for the Fourth Quarter 2024

Consensus EPS estimates upgraded to US$0.30 loss, revenue downgraded

Price target decreased by 9.6% to US$3.92

Consensus EPS estimates fall by 16%

Recent updates

Consensus EPS estimates upgraded to US$0.24 loss, revenue downgraded

New minor risk - Profitability

Chairman & CEO recently bought US$422k worth of stock

OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

OPKO Health, Inc. Provides Financial Guidance for the Fourth Quarter 2024

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

OPKO Health, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Not Enough To Keep OPKO Health Flying

Consensus EPS estimates upgraded to US$0.30 loss, revenue downgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

OPKO Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

OPKO Health, Inc. (NasdaqGS:OPK) announces an Equity Buyback for $100 million worth of its shares.

OPKO Health, Inc. announced that it has received $250 million in funding from Healthcare Royalty Management, LLC

Price target decreased by 9.6% to US$3.92

OPKO Health, Inc. announced that it has received $250 million in funding from Healthcare Royalty Management, LLC

Chairman & CEO recently bought US$127k worth of stock

Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

OPKO Health, Inc. announced delayed annual 10-K filing

New major risk - Financial position

Full year 2023 earnings: EPS exceeds analyst expectations

Chairman & CEO recently bought US$992k worth of stock

OPKO Health, Inc. to Report Q4, 2023 Results on Feb 27, 2024

OPKO Health, Inc., Annual General Meeting, Mar 28, 2024

Chairman & CEO recently bought US$1.5m worth of stock

President & Vice Chairman recently bought US$514k worth of stock

New minor risk - Profitability

OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar

Chairman & CEO recently bought US$1.3m worth of stock

Consensus EPS estimates fall by 16%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

OPKO Health, Inc. Presents Late-Breaking Clinical Data on RAYALDEE Extended-Release Calcifediol

OPKO Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is OPKO Health (NASDAQ:OPK) A Risky Investment?

Chairman & CEO recently bought US$176k worth of stock

Chairman & CEO recently bought US$1.2m worth of stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

OPKO Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023

OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up

New minor risk - Profitability

Consensus estimates of losses per share improve by 16%

Price target decreased by 11% to US$4.32

Would OPKO Health (NASDAQ:OPK) Be Better Off With Less Debt?

Consensus EPS estimates upgraded to US$0.25 loss

Chief Innovation Officer & Director recently bought US$541k worth of stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chairman & CEO recently bought US$264k worth of stock

Chairman & CEO recently bought US$1.2m worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 36%

OPKO Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Is OPKO Health (NASDAQ:OPK) Using Too Much Debt?

Price target decreased to US$4.95

Chairman & CEO recently bought US$447k worth of stock

Chairman & CEO recently bought US$319k worth of stock

Chairman & CEO recently bought US$319k worth of stock

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

OPKO Health, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chairman & CEO recently bought US$182k worth of stock

Chairman & CEO recently bought US$133k worth of stock

Chairman & CEO recently bought US$413k worth of stock

OPKO Health: Assessing If Significant Potential Can Be Realized

Chairman & CEO recently bought US$214k worth of stock

OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt

Chairman & CEO recently bought US$508k worth of stock

OPKO Health, Inc. Announces Leadership Changes for Bioreference Laboratories

Chairman & CEO recently bought US$802k worth of stock

OPKO Health, Inc. Provides Revenue Guidance for the Year 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

OPKO Health, Inc. to Report Q2, 2022 Results on Aug 04, 2022